» Articles » PMID: 19295504

Predictive Biomarkers in the Development of Oncology Drugs: a Therapeutic Industry Perspective

Overview
Publisher Wiley
Specialty Pharmacology
Date 2009 Mar 20
PMID 19295504
Citations 8
Authors
Affiliations
Soon will be listed here.
Citing Articles

Hypoxia-targeted drug delivery.

Sharma A, Arambula J, Koo S, Kumar R, Singh H, Sessler J Chem Soc Rev. 2018; 48(3):771-813.

PMID: 30575832 PMC: 6361706. DOI: 10.1039/c8cs00304a.


Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses.

Ruhaak L, Taylor S, Miyamoto S, Kelly K, Leiserowitz G, Gandara D Anal Bioanal Chem. 2013; 405(14):4953-8.

PMID: 23525540 PMC: 3640767. DOI: 10.1007/s00216-013-6908-z.


Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration.

Martell R, Sermer D, Getz K, Kaitin K Oncologist. 2012; 18(1):104-11.

PMID: 23263289 PMC: 3556246. DOI: 10.1634/theoncologist.2012-0235.


Quantifying factors for the success of stratified medicine.

Trusheim M, Burgess B, Hu S, Long T, Averbuch S, Flynn A Nat Rev Drug Discov. 2011; 10(11):817-33.

PMID: 22037040 DOI: 10.1038/nrd3557.


Predictive biomarkers: a paradigm shift towards personalized cancer medicine.

La Thangue N, Kerr D Nat Rev Clin Oncol. 2011; 8(10):587-96.

PMID: 21862978 DOI: 10.1038/nrclinonc.2011.121.